In autoimmune diseases such as RA, anti-TNF biologics are now routinely administered and improve life quality for many patients, and, in cancer, we have recently witnessed the success of combined anti-CTLA4 and anti-PD-L1/PD-1 in the treatment of melanoma [171]. This evidence concerns the gene CD274 and rheumatoid arthritis.